Valeant closing in on $160-per-share Salix deal: Reuters

Carly Helfand There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters' sources, serial acquirer Valeant has the lead. FiercePharma ...

Ex-Merck analyst pleads guilty to insider trading

Eric Palmer Former Merck analyst Zachary Zwerko pleaded guilty to federal insider-trading charges on Thursday for passing merger tips to a business school chum. The tips allowed the ...

Sanofi’s got a new CEO. Now what?

Damian Garde Sanofi has made official what's no longer news, trotting out Olivier Brandicourt as its next chief executive. Stepping in on April 2, the experienced Frenchman inherits ...

UPDATED: Cellectis files for $115M IPO as CAR-T tech sizzles

John Carroll PARIS–Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $ 115 million in the hot American market as it pushes ...

Brandicourt’s departure piles on the exec shuffling at Bayer

Carly Helfand With the hire of Bayer's Olivier Brandicourt as its new CEO, Sanofi will fill the hole it created when it ousted helmsman Chris Viehbacher nearly four months ago. ...

Lilly extends study of highly anticipated cholesterol fighter

Eric Palmer Eli Lilly says it will extend the massive Phase III trial for its highly anticipated drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," ...

Biotech bonanza helps Bessemer roll out a $1.6B venture fund

John Carroll Bessemer Venture Partners is rolling out a new, global fund with $ 1.6 billion to invest in a range of new technologies–including biotech. FierceBiotech News

Want Actavis? Prepare to pay up, CEO says

Carly Helfand Actavis CEO Brent Saunders expects pharma's deal wave to continue. But make no mistake, he says: Potential suitors are going to have to pony up a pretty penny if they ...

Biotech IPOs slump as Inotek comes in low and Carbylan strikes out

Damian Garde The frothy market for biotech debuts is looking a bit less promising this week as one entrant priced well below its hoped-for range and another called off its IPO altogether. FierceBiotech ...

Actavis has an eye on more deals, for ‘couple billion dollars’ or so

Damian Garde Actavis, still awaiting the close of its $ 66 billion buyout of Allergan, is on the lookout for more bolt-on acquisitions. FierceBiotech News

Residents want to sue Roche before it gives up New Jersey campus

Eric Palmer Roche closed its Clifton, NJ, campus in 2013 and hopes to be free of the property this year. But some area residents want to slap the Swiss drugmaker with a lawsuit before ...

Novartis makes Israel a priority, U.K. dreams up Alzheimer’s R&D hub, Shire defends tax model

Nick Paul Taylor In this week's EuroBiotech Report, Novartis is getting deeper into the Israeli biotech scene, tasking BioLineRx with keeping tabs on local startups after realizing ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS